TY - JOUR
T1 - Mesenchymal stem cells in ex vivo cord blood expansion
AU - Robinson, Simon N.
AU - Simmons, Paul J.
AU - Yang, Hong
AU - Alousi, Amin M.
AU - Marcos De Lima, J.
AU - Shpall, Elizabeth J.
N1 - Funding Information:
This work was supported in part by NIH Grant # RO1-CA061508-15 and Cancer Prevention & Research Institute of Texas (CPRIT) Grant # RP100469 .
PY - 2011/3
Y1 - 2011/3
N2 - Umbilical cord blood (CB) is becoming an important source of haematopoietic support for transplant patients lacking human leukocyte antigen matched donors. The ethnic diversity, relative ease of collection, ready availability as cryopreserved units from CB banks, reduced incidence and severity of graft versus host disease and tolerance of higher degrees of HLA disparity between donor and recipient, are positive attributes when compared to bone marrow or cytokine-mobilized peripheral blood. However, CB transplantation is associated with significantly delayed neutrophil and platelet engraftment and an elevated risk of graft failure. These hurdles are thought to be due, at least in part, to low total nucleated cell and CD34 + cell doses transplanted. Here, current strategies directed at improving TNC and CD34 + cell doses at transplant are discussed, with particular attention paid to the use of a mesenchymal stem cell (MSC)/CB mononuclear cell ex vivo co-culture expansion system.
AB - Umbilical cord blood (CB) is becoming an important source of haematopoietic support for transplant patients lacking human leukocyte antigen matched donors. The ethnic diversity, relative ease of collection, ready availability as cryopreserved units from CB banks, reduced incidence and severity of graft versus host disease and tolerance of higher degrees of HLA disparity between donor and recipient, are positive attributes when compared to bone marrow or cytokine-mobilized peripheral blood. However, CB transplantation is associated with significantly delayed neutrophil and platelet engraftment and an elevated risk of graft failure. These hurdles are thought to be due, at least in part, to low total nucleated cell and CD34 + cell doses transplanted. Here, current strategies directed at improving TNC and CD34 + cell doses at transplant are discussed, with particular attention paid to the use of a mesenchymal stem cell (MSC)/CB mononuclear cell ex vivo co-culture expansion system.
KW - cord blood (CB) transplantation
KW - ex vivo expansion
KW - mesenchymal stem cells (MSC)
UR - http://www.scopus.com/inward/record.url?scp=79952597009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952597009&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2010.11.001
DO - 10.1016/j.beha.2010.11.001
M3 - Review article
C2 - 21396596
AN - SCOPUS:79952597009
SN - 1521-6926
VL - 24
SP - 83
EP - 92
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 1
ER -